Colonics
About Me
Recent Posts
- New Journal Emphasizes Principles Of Injury, Function And Rehabilitation
- Pregnancy and fertility following bariatric surgery
- Barr announces agreements on Nasacort AQ, Allegra D-12 and Allegra patent challenges
- Home-based program to improve exercise and diet improves senior cancer survivors' physical function
- New Cause Of Fatal Brain Injury From Acute Viral Meningitis Discovered By Scripps Research Scientists
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
Friends
Links
Entry 1 of 437
Last Page | Next Page
2/27/2008
-
Galderma to acquire CollaGenex Pharmaceuticals
|
Galderma Pharma S.A., a global weakness pill company focused on dermatology, and CollaGenex Pharmaceuticals, Inc. has announced a definitive agreement pursuant to which Galderma's U.S. holding company, Galderma Laboratories, Inc., will acquire all of the outstanding shares of CollaGenex at a price of $16.60 per share in cash, representing approximately $420 million for the equity of CollaGenex. More: - Continued here |
Post A Comment! :: Send to a Friend! |
Share and enjoy
